Concert Pharmaceuticals Inc

NASDAQ:CNCE   3:59:55 PM EDT
7.08
-0.12 (-1.67%)
Products, Regulatory, Earnings Announcements

Concert Pharmaceuticals Reports Positive Topline Results For Second CTP‑543 Phase 3 Clinical Trial In Alopecia Areata

Published: 08/01/2022 12:07 GMT
Concert Pharmaceuticals Inc (CNCE) - Concert Pharmaceuticals Reports Positive Topline Results for Second Ctp‑543 Phase 3 Clinical Trial in Alopecia Areata.
Concert Pharmaceuticals Inc - Thrive-aa2 Study Met Primary Endpoint for Scalp Hair Regrowth.
Concert Pharmaceuticals Inc - Key Secondary Endpoint Met for Patient Reported Outcome on Hair Satisfaction.
Concert Pharmaceuticals Inc - Key Secondary Endpoint Met for Hair Regrowth As Early As 12 Weeks.
Concert Pharmaceuticals Inc - Ctp-543 Has Potential to Be Best-in-class for Treatment of Alopecia Areata.
Concert Pharmaceuticals - Completes Pivotal Program With Two Positive Phase 3 Trials and Expects to File New Drug Application in First Half of 2023.
Revenue is expected to be $0.17 Million
Adjusted EPS is expected to be -$0.59

Next Quarter Revenue Guidance is expected to be $0.17 Million
Next Quarter EPS Guidance is expected to be -$0.59

More details on our Analysts Page.